• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
TSLP Signaling Pathway in Oncology Drug Pipeline Update 2015 Product Image

TSLP Signaling Pathway in Oncology Drug Pipeline Update 2015

  • ID: 2067704
  • January 2015
  • Region: Global
  • Bioseeker

Thymic stromal lymphopoietin (TSLP) is an IL-7-like cytokine that play various roles in a broad spectrum of biological procedures. TSLP can be secreted by epithelial cells upon pathogen stimulation. TSLP can also activate dendritic cells, CD4+ T cells and CD8+ T cells. TSLP not only activate the JAK/STAT pathway but also induce phosphorylation of other signaling molecules including PI3K/Akt, ERK1/2 and JNKs. Aberrant TSLP signaling is implicated in a number of the development of diseases, including asthma, atopic dermatitis, eosinophilic eosophagitis and acute lymphoid leukemia.

There are today 198 companies plus partners developing 228 TSLP pathway targeting drugs in 1035 developmental projects in cancer. In addition, there is 1 suspended drug and the accumulated number of ceased drugs over the last years amount to another 167 drugs. Tslp Signaling Pathway In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 172 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 170 out of the 172 studied drug targets so far have READ MORE >

Note: Product cover images may vary from those shown



Delivery Format: Desktop App plus Online Access to Updates (One Year)

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Photocure ASA Roche Diagnostics Ltd. Abbott Laboratories Ltd. Pfizer, Inc. Novartis AG Becton, Dickinson and Company (BD)